<DOC>
	<DOCNO>NCT02879526</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety Chidamide Combined With Cyclophosphamide、Prednisone、Thalidomide Treatment Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma : Phase II , Single-arm , Open-label , Muti-center Study</brief_summary>
	<brief_title>Chidamide Combined With Cyclophosphamide、Prednisone、Thalidomide Treatment Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma</brief_title>
	<detailed_description>Chidamide new histone deacetylase inhibitor show anti-tumor activity Relapse/Refratory Peripheral T Cell Lymphoma.Cyclophosphamide、Prednisone、Thalidomide ( CPT ) oral combination regimen lymphoma patient stand standard chemotherapy . The investigator therefore design open-label , phase II , single-arm trial investigate efficacy Chidamide Combined With CPT treatment fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma Primary Outcome Measures : • overall response rate Secondary Outcome Measures : - duration response - progression free survival - overall survival Enrollment:45 Study Start Date : August 2016 Primary Completion Date : March 2018</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Histologically confirm Peripheral T Cell Lymphoma , exclude NK/T cell lymphoma 2 . Relapse refractory least one prior therapy ( chemotherapy stem cell transplantation ) 3. 4. age 18 75 , gender 5 . ECOG PS 01 6 . Peripheral ANC &gt; 1.5*109/L ; platelet &gt; 70*109/L ; Hb≥ 90g/L 7 . Anticipated survival ≥ 3 month 8 . No chemotherapy 、radiotherapy stem cell transplantation within 4 week inclusion 9 . Sign inform consent form , adherence study visit schedule protocol requirement 1 . Pregnant woman woman suckle period Potentia Generand willing take contraceptive 2 . New York Heart Association class III IV cardiac failure ; oror history follow disease past 6 month : acute coronary syndrome , acute heart failure , severe ventricular arrhythmia 3 . Poor hepatic function , define total bilirubin 1.5 fold upper normal level , ALT , AST 2 fold upper normal level 5fold upper normal level hepatic involvement ; Poor renal function , define serum creatinine 1.5 fold upper normal level 4 . CNS meningeal involvement 5. intervention myelosuppression within7 day inclusion 6. patient active bleed 7 . Major surgery within three week inclusion 8 . Positive HIV , syphilis , HCV , HBV virus load ( HBV DNA ) &gt; 1×105 copies/ml ; 9 . Any psychological condition may disturb consent . 10 . In condition investigator consider ineligible 11 . Known sensitivity allergy investigational Product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Relapse/Refratory Peripheral T Cell Lymphoma</keyword>
	<keyword>Chidamide</keyword>
	<keyword>Cyclophosphamide、Prednisone、Thalidomide ( CPT )</keyword>
</DOC>